Sylvia Zhao
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Melanoma and MAPK Pathways, Synthesis and biological activity, Pharmacogenetics and Drug Metabolism, Liver physiology and pathology
Most-Cited Works
- → RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models(2010)402 cited
- → Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer(2018)329 cited
- → Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite(2020)68 cited
- → The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma(2019)66 cited
- → Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts(2019)61 cited
- → A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma(2019)49 cited
- → Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.(2014)45 cited
- → Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.(2014)44 cited
- → The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia(2023)28 cited
- → Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation(2022)26 cited